English Українська
  • Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    Tkachenko M. V.

    HYPOURICEMIC THERAPY FOR PREVENTION AND TREATMENT OF THE STORAGE: ACTUAL STATE OF THE PROBLEM


    About the author: Tkachenko M. V.
    Heading LITERATURE REVIEWS
    Type of article Review article
    Annotation Gout is one of the most common rheumatologic diseases affecting joints in Ukraine and in the world. In Ukraine, the prevalence of gout is 0.4% of the adult population, the prevalence of hyperuricemia is 15-20% . Preventing future gouty attacks requires a reduction in uric acid levels in the serum, which contributes to the dissolution of urat crystals, this occurs by reducing the synthesis of uric acid in serum and increasing its excretion by the kidneys. Inhibitors of xanthine oxidase (ICO), such as allopurinol and febuxostat, are first-line drugs for the prevention of acute gouty attacks. Probenecid (a uricosuric agent) is an auxiliary or second-line drug that is used when an ICE is contraindicated or poorly tolerated. Recently, several drugs of the third line (for example, pioglitaca, lezinuride) have become available for the treatment of refractory gout.
    Tags giperurikemia, gout, hypokalemic therapy, gout attack
    Bibliography
    • Becker M. A. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy / M. A. Becker, P. H. MacDonald, B. J. Hunt [et al.] // Nucleosides Nucleotides Nucleic Acids. – 2008. – 27(6). – Р. 585-591.
    • Choi H. K. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey / H. K. Choi, S. Liu, G. Curhan // Arthritis Rheum. – 2005. – 52(1). – Р. 283-289.
    • Choi H. K. Soft drinks, fructose consumption and the risk of gout in men: prospective cohort study / H. K. Choi, G. Curhan // BMJ. – 2008. – 336(7639). – Р. 309-312.
    • Deerfield I. L. Uloric (febuxostat) package insert.: Takeda Pharmaceuticals America, Inc; March - 2013.
    • Grassi D. Therapeutic approaches to chronic hyperuricemia and gout / D. Grassi, R. Pontremoli, R. Bocale [et al.] // High Blood Press Cardiovasc Prev. – 2014. – 21(4). – Р. 243-250.
    • Hunter D. J. Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study / D. J. Hunter, M. York, C. E. Chaisson [et al.] // J Rheumatol. – 2006. – 33(7). – Р. 1341-1345.
    • Khanna D. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia / D. Khanna, J. D. Fitzgerald, P. P. Khanna [et al.] // Arthritis Care Res. – 2012. – 64(10). – Р. 1431-1446.
    • Khanna D. American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis / D. Khanna, P. P. Khanna, J. D. Fitzgerald [et al.] //Arthritis Care Res. – 2012. – 64(10). – Р. 1447-1461.
    • Glendale W. I. Krystexxa (pegloticase) package insert / W. I. Glendale //: Crealta Pharmaceuticals LLC; December - 2014.
    • Neogi T. Gout N Engl J Med. – 2011. – 364(5). – P. 443-452.
    • New Castle D. E. Probenecid package insert.: Marlex Pharmaceuticals, Inc; May - 2013.
    • Qaseem A. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians / A. Qaseem, R. P. Harris, M. A. Forciea // Ann Intern Med. – 2017. – 166(1). – Р. 58-68.
    • Richette P. 2016 updated EULAR evidence-based recommendations for the management of gout / P. Richette, M. Doherty, E. Pascual [et al.] //Ann Rheum Dis. – 2017. – 76. – Р. 29-42.
    • Schumacher H. R. Jr. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study / H. R. Jr. Schumacher, M. A. Becker, E. Lloyd [et al.] // Rheumatology. – 2009. – 48(2). – 188-194.
    • Stamp L. K. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment / L. K. Stamp, J. L. O'Donnell, M. Zhang [et al.] //Arthritis Rheum. – 2011. – 63(2). – Р. 412-421.
    • Schumacher H. R. Jr. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study / H. R. Jr. Schumacher, R. R. Evans, K. G. Saag [et al.] // Arthritis Care Res. – 2012. – 64(10). – Р. 1462-1470.
    • Shuba N. M. Hyperuricemia – Multimorbid pathology in rheumatology / N. M. Shuba // Ukr rheumatol Zh. – 2013. – 2 (52). – Р. 14-22.
    • Shuba N. M. Gout - Multimorbid Pathology / N. M. Shuba, T. D. Voronova // Ukr rheumatol Zh. – 2015. – 59 (1). – Р. 72-83.
    • Vadhan-Raj S. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome / S. Vadhan-Raj, L. E. Fayad, M. A. Fanale [et al.] //Ann Oncol. – 2012. – 23(6). – Р. 1640-1645.
    • Wilmington D. E. Zurampic (lesinurad) package insert / D. E. Wilmington // -: Astra Zeneca Pharmaceuticals LP; - 2015.
    • Wilson L. Gouty arthritis: a review of acute management and prevention / L. Wilson, J. J. Saseen // Pharmacotherapy. – 2016. – 36(8). – Р. 906-922.
    • Zhu Y. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008 / Y. Zhu, B. J. Pandya, H. K. Choi [et al.] // Arthritis Rheum. – 2011. – 63(10). – Р. 3136-3141.
    Publication of the article «World of Medicine and Biology» №4(62), 2017 year, 197-203 pages, index UDK 616 – 002.78:616 – 085
    DOI 10.26724/2079-8334-2017-4-62-197-203